title: Giant cavernous hemangioma of the liver: is tumor size a risk factor for hepatectomy?
abstract: The aim of this study was to evaluate whether hepatic giant cavernous hemangioma (GCH) tumor size is a risk factor for hepatectomy. Twenty patients with GCH of the liver were treated by hepatic resection. Eleven patients with maximum resected specimen tumor size of >10 cm (mean tumor size, 18.5 cm; group 1) were compared with the 9 patients with tumor size. <10 cm (mean tumor size, 8.6 cm; group 2). The incidence of major hepatectomy in group 1 was significantly higher than that in group 2 (P = 0.0241). Although there were no significant differences in preoperative liver function, or in fibrinogen or platelet counts between the two groups, the level of preoperative fibrin degradation product (FDP) in group 1 was significantly higher than that in group 2 (P = 0.0116). Mean intraoperative hemorrhage volume, blood transfusion volume, and operation time in group 1 vs group 2 were 7003 ml vs 1092 ml (P = 0. 0251), 2927 ml vs 556 ml (P = 0.0169), and 431 min vs 216 min (P < 0. 0001), respectively. The incidence of postoperative complications in group 1 (45.5%) was higher than that in group 2 (22.2%), although not significantly so. There was no operative mortality in either group. Tumor size significantly correlated with intraoperative blood loss, operation time, weight of resected liver, intraoperative blood transfusion volume, and preoperative FDP levels. GCH tumor size is a significant risk factor for hepatectomy mainly because of the massive intraoperative blood loss and blood transfusion associated with major hepatic resection. More careful preoperative management to decrease tumor size may increase the safety of surgery for GCH of the liver.
authors.affiliation: Second Department of Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hanazaki
authors.forename: S
authors.initials: S
authors.lastname: Kajikawa
authors.forename: A
authors.initials: A
authors.lastname: Matsushita
authors.forename: T
authors.initials: T
authors.lastname: Monma
authors.forename: M
authors.initials: M
authors.lastname: Hiraguri
authors.forename: N
authors.initials: N
authors.lastname: Koide
authors.forename: Y
authors.initials: Y
authors.lastname: Nimura
authors.forename: W
authors.initials: W
authors.lastname: Adachi
authors.forename: J
authors.initials: J
authors.lastname: Amano
mesh_terms: D000328:Adult; D000368:Aged; D016063:Blood Loss, Surgical / Q000503:physiopathology; D016009:Chi-Square Distribution; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006392:Hemangioma, Cavernous / Q000097:blood / Q000473:pathology* / Q000601:surgery*; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D005338:Fibrin Fibrinogen Degradation Products